SMO and skin basal cell carcinoma: Cyclopamine was subsequently demonstrated to bind to and inhibit SMO [26], and based on these early findings, several additional SMO antagonists have been developed and tested clinically, including vismodegib and sonidegib, which are approved for advanced BCC, and glasdegib for AML.